TrialA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Trial details
- Registry ID
- NCT07355075
- Phase
- Phase 2, Phase 3
TTRX
Turn Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)NCT07355075 | Turn Therapeutics | Phase 2, Phase 3 | Recruiting | 2027-01-20Estimated |
Latest recorded trial changes
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
NCT07355075 · Turn Therapeutics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change in Investigator Global Assessment (IGA) at Week 8
+ After
Measure: vIGA-AD Success at Week 4 Measure: EASI-75 at Week 4 Measure: EASI-90 at Week 8 Measure: EASI-100 at Week 8
Planned enrollment increased by 80 participants
− Before
110 participants (planned)
+ After
190 participants (planned)
Primary completion date changed
− Before
10 Jul 2026
+ After
20 Jan 2027
Phase changed
− Before
PHASE2
+ After
PHASE2, PHASE3
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
NCT07355075 · Turn Therapeutics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change in Eczema Area and Severity (EASI)
+ After
Measure: Change in Investigator Global Assessment (IGA) at Week 8
Planned enrollment increased by 10 participants
− Before
100 participants (planned)
+ After
110 participants (planned)
Primary completion date changed
− Before
31 May 2026
+ After
10 Jul 2026